Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (the TRAFFIC study): A Randomized Trial - TRAFFIC


This was a phase II multicenter, randomized, double-blind, placebo-controlled trial designed to compare the effects of intra-arterial infusions of recombinant fibroblast growth factor-2 (rFGF-2) with placebo on exercise capacity in patients with moderate to severe lower extremity claudication.